Navigation Links
Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Date:9/14/2009

SUNNYVALE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the fourth quarter and fiscal year ended June 30, 2009 after the NASDAQ market closes on Thursday September 17, 2009 at 1:30 p.m. PDT (4:30 p.m. EDT). To participate in the conference call, please dial 866-642-7062 for domestic callers and 706-643-1591 for international callers. The conference ID is 30472935. To access the audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available on the company's website for one month.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us athttp://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
2. Pharmacyclics, Inc. Rights Offering Oversubscribed
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
5. Pharmacyclics Files Registration Statement for Rights Offering
6. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
7. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
8. Pharmacyclics Secures $5.0 Million in Debt Financing
9. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
10. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
11. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Alex,s Lemonade Stand Foundation (ALSF), a leading national ... a state-of-the-art bioinformatics lab, using ,big data, to advance ... as Liz Scott , co-executive director of ALSF ... in Washington, D.C. , hosted by ... advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):